<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950270</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-AOJCE20-BL-XPRESSE</org_study_id>
    <nct_id>NCT04950270</nct_id>
  </id_info>
  <brief_title>Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome</brief_title>
  <acronym>XPRESSE</acronym>
  <official_title>The Arginine Vasopressin aXis as a Potential Therapeutic Target for Posterior REverSible Encephalopathy SyndromE (XPRESSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      XPRESSE is a multicenter observational prospective biomarker study in which critically ill&#xD;
      patients with MRI-based PRES diagnosis will have copeptin kinetics from a daily blood sample&#xD;
      for 6 days and a 3-month follow-up. This study aims to investigate the relationship between&#xD;
      copeptin and PRES in order to establish the optimal therapeutic time window for vaptan&#xD;
      treatment against PRES.&#xD;
&#xD;
      Data collection using an electronic case report form will include demographic data, medical&#xD;
      history and data related to PRES: onset modalities and date of symptoms control, radiological&#xD;
      features of PRES, biological investigations, results of etiological investigations and&#xD;
      therapeutic management (e.g., anticonvulsants, antihypertensive drugs, supportive&#xD;
      treatments). Outcomes will include modified Rankin scale score and Glasgow Outcome Scale&#xD;
      score at ICU discharge, 3-month modified Rankin Scale score and 3-month mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological entity&#xD;
      associating various neurological manifestations (e.g., encephalopathy, seizures) with a&#xD;
      typical subcortical brain edema. While the pathophysiology of PRES remains elusive, the&#xD;
      involvement of the arginine vasopressin (AVP) axis has recently been suggested by its&#xD;
      stimulation in almost all etiologies of PRES as well as by its pathogenesis in the generation&#xD;
      of brain edema that has been established in different preclinical models (e.g., traumatic&#xD;
      brain injury, intracerebral hemorrhage) (Largeau et al., Mol Neurobiol 2019 - PMID:&#xD;
      30924075). Copeptin, a stable peptide derived from the same precursor as AVP and released in&#xD;
      an equimolar ratio to AVP, is largely used in vivo to monitor AVP secretion. In a series of&#xD;
      225 critically ill patients free from PRES, median copeptin admission level was 50 pmol/L&#xD;
      (Krychtiuk et al., PLOS ONE 2017- PMID: 28118414). By analogy to copeptin kinetics in&#xD;
      patients with traumatic brain injury (Dong et al., J Trauma 2011 - PMID: 21502880), copeptin&#xD;
      could attain peak level during the first week of PRES.&#xD;
&#xD;
      Blocking vasopressin receptors with vaptan appears to be a promising approach for PRES&#xD;
      treatment. This study aims to investigate the relationship between copeptin and PRES in order&#xD;
      to establish the optimal therapeutic time window for vaptan treatment against PRES.&#xD;
&#xD;
      XPRESSE is a multicenter observational prospective biomarker study in which critically ill&#xD;
      patients in 4 French ICUs with MRI-based PRES diagnosis will have copeptin kinetics from a&#xD;
      daily blood sample for 6 days and a 3-month follow-up.&#xD;
&#xD;
      Data collection using an eCRF will include demographic data, medical history and data related&#xD;
      to PRES: onset modalities and date of symptoms control, radiological features of PRES,&#xD;
      biological investigations, results of etiological investigations and therapeutic management&#xD;
      (e.g., anticonvulsants, antihypertensive drugs, supportive treatments). Outcomes will include&#xD;
      modified Rankin scale score and Glasgow Outcome Scale score at ICU discharge, 3-month&#xD;
      modified Rankin Scale score and 3-month mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of time to maximum blood copeptin concentration (Tmax)</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
    <description>Tmax will be estimated from copeptin kinetics: 6 samples at about 24 hours interval during the first 6 days of ICU stay with PRES</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of Tmax according to the etiology of PRES</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Tmax according to the type of MRI-based brain edema at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
    <description>Diffusion-weighted imaging (DWI) sequences and Apparent diffusion coefficient (ADC) maps will be used to discriminate a cytotoxic pattern of edema from a vasogenic edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Area Under the Curve from D0 to D5 (AUC D0-D5) of blood copeptin according to the etiology of PRES</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
    <description>AUC D0-D5 will be estimated from copeptin kinetics: 6 samples at about 24 hours interval during the first 6 days of ICU stay with PRES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of AUC D0-D5 of blood copeptin according to the type of MRI-based brain edema at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
    <description>DWI sequences and ADC maps will be used to discriminate a cytotoxic pattern of edema from a vasogenic edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of time to reach a copeptin concentration ≤50 pmol/L according to the etiology of PRES</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of time to reach a copeptin concentration ≤50 pmol/L according to the type of MRI-based brain edema at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
    <description>DWI sequences and ADC maps will be used to discriminate a cytotoxic pattern of edema from a vasogenic edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation analysis between AUC D0-D5 of blood copeptin and the extent of T2-FLAIR hyperintensities at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation analysis between AUC D0-D5 of blood copeptin and ADC values at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association analysis between AUC D0-D5 of blood copeptin and cerebral hemorrhagic lesions at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association analysis between AUC D0-D5 of blood copeptin and contrast enhancement in the brain at diagnosis</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation analysis between AUC D0-D5 of blood copeptin and AUC D0-D5 of mean arterial pressure</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation analysis between AUC D0-D5 of blood copeptin and AUC D0-D5 of serum creatinine</measure>
    <time_frame>Up to 120 hours post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association analysis between AUC D0-D5 of blood copeptin and Glasgow Outcome Scale score &lt; 4 at ICU discharge</measure>
    <time_frame>0, 24, 48, 72, 96, 120 hours post-baseline and ICU discharge</time_frame>
    <description>Glasgow Outcome Scale score: [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5: Low disability]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association analysis between AUC D0-D5 of blood copeptin and modified Rankin Scale score ≥ 4 at 3-month follow-up</measure>
    <time_frame>0, 24, 48, 72, 96, 120 hours post-baseline and 3 months</time_frame>
    <description>Day-90 modified Rankin scale will be determined during a structured phone interview.&#xD;
Modified Rankin Scale score: [0: No symptoms at all, 1: No significant disability, 2: Slight disability, 3: Moderate disability, 4: Moderately severe disability, 5: Severe disability]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association analysis between AUC D0-D5 of blood copeptin and mortality at 3-month follow-up</measure>
    <time_frame>0, 24, 48, 72, 96, 120 hours post-baseline and 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Posterior Reversible Encephalopathy Syndrome</condition>
  <arm_group>
    <arm_group_label>Group</arm_group_label>
    <description>Critically ill adult patients meeting all eligibility criteria with MRI-based PRES diagnosis within the last 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood copeptin monitoring</intervention_name>
    <description>Blood copeptin monitoring during the first 6 days of ICU stay with PRES</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>phone interview</intervention_name>
    <description>Structured phone interview at 3 months to collect vital status and modified Rankin Scale score</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill adult patients in ICU with PRES&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years ;&#xD;
&#xD;
          -  Obtaining the non-opposition ;&#xD;
&#xD;
          -  Patient hospitalized in ICU;&#xD;
&#xD;
          -  PRES diagnosed within the last 48 hours (before admission or during ICU stay), based&#xD;
             on the following clinico-radiological criteria :&#xD;
&#xD;
               -  Presentation with acute clinical symptoms ;&#xD;
&#xD;
               -  Presence of known risk factor for PRES;&#xD;
&#xD;
               -  Distributions of T2 weighted imaging (T2WI) or T2-fluid attenuated inversion&#xD;
                  recovery (T2-FLAIR) hyperintensities compatible with PRES imaging patterns ;&#xD;
&#xD;
               -  No other possible causes of these neuroimaging abnormalities found.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under legal protection ;&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bérenger LARGEAU, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte SALMON GANDONNIERE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte SALMON GANDONNIERE, MD, PhD</last_name>
    <phone>(+33)2 47 47 38 55</phone>
    <email>charlotte.salmon.gandonniere@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean REIGNIER, MD, PhD</last_name>
      <email>jean.reignier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean REIGNIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Grégoire MULLER, MD</last_name>
      <email>gregoire.muller@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Grégoire MULLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Flora DELAMAIRE, MD</last_name>
      <email>Flora.DELAMAIRE@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit PAINVAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flora DELAMAIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte SALMON GANDONNIERE, MD, PhD</last_name>
      <phone>(+33)2 47 47 38 55</phone>
      <email>charlotte.salmon.gandonniere@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Charlotte SALMON GANDONNIERE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Posterior Leukoencephalopathy Syndrome</keyword>
  <keyword>Antidiuretic hormone</keyword>
  <keyword>Intensive Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Posterior Leukoencephalopathy Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

